MET233i
PF-08653945 · PF’3945 · Pfizer / Metsera
Long-acting amylin analogue with dual amylin/calcitonin activity.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: Pfizer lists monotherapy in Phase 2 obesity development.
Next: Phase 2 dose and dosing-interval results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
SOLIS-1 · PF-08653945 monotherapy arms
Weight management / amylin monotherapyAdults with overweight or obesity; the SOLIS-1 master trial includes PF-08653945 monotherapy and combination arms. This profile refers to the amylin-analogue component.
